72.6 F
Fort Worth
Saturday, September 19, 2020
- Advertisements -
Health Care Fort Worth pharmaceutical development company to present at BIO CEO and Investor...

Fort Worth pharmaceutical development company to present at BIO CEO and Investor Conference

Other News

Wall Street posts solid gains after surge in corporate deals

By ALEX VEIGA and DAMIAN J. TROISE AP Business Writers Wall Street kicked off the week with a broad...

Tarrant County ranks low in work-from-home study by NAR

North Texas ranks pretty high in the “Work from Home” category, according to a just-released study by the National Association of Realtors....

Commentary: Universities and COVID-19: Charting turbulent times

Ray Perryman As the COVID-19 pandemic emerged this spring, college campuses across the United States swiftly sent students...

Linear Labs introduces electric motor that will fit inside a pocket

Leading the new wave of electrification, a Fort Worth-based technology company has built an electric motor that can fit inside one's pocket,...
Paul Harral
Paul is a lifelong journalist with experience in wire service, newspaper, magazine, local and network television and digital media. He was vice president and editor of the editorial page of the Fort Worth Star-Telegram and editor of Fort Worth, Texas magazine before joining the Business Press. What he likes best is writing about people in detail and introducing them to others in the community. Specific areas of passion are homelessness, human trafficking, health care and aerospace.

Fort Worth-based NanOlogy, a clinical stage pharmaceutical development company, has announced that Gere diZerega, MD, VP of Medical Affairs, will present at the BIO CEO & Investor Conference, Feb. 12 in New York, to share “promising preliminary data from the NanOlogy clinical development programs.

The company is developing a submicron particle technology system for local delivery of chemotherapeutic agents for the treatment of cancer and related illnesses where the drugs are injected directly to the affected area or organ. It is also developing a topical administration treatment.

NanOlogy LLC (www.nanology.us) is a company formed by DFB Pharmaceuticals of

Fort Worth, CritiTech Inc. of Lawrence, Kansas, and US Biotest Inc. of San Luis Obispo, California.

“The NanOlogy submicron particle platform may provide more effective therapies for multiple

indications either as early first line treatments or in combination regimens,” lead scientific

advisor Maurie Markman, MD, President of Medicine and Science, Cancer Treatment Centers of

America, said in the news release.

“Early trial results indicate that the platform may enable local delivery of large, sustained amounts of the drug at the site of disease, thereby reducing systemic exposure and systemic side effects.”

One side effect that the company is hoping to avoid is the illness caused by both cancer fight drugs and the solution used to deliver them that accompany traditional chemotherapy.

NanOlogy has four Phase 2 clinical trials underway for NanoPac, a sterile suspension of

submicron particle paclitaxel, in ovarian cancer, prostate cancer, pancreatic cancer and pancreatic mucinous cysts. NanOlogy also is conducting a Phase 2 trial of SOR007, submicron particle paclitaxel suspended in a topical anhydrous base, for cutaneous metastases, while NanOlogy affiliate, DFB Soria, has a Phase 2 trial of SOR007 nearing completion for actinic keratosis. In 2018, a clinical trial is planned in bladder cancer for

NanoDoce, a sterile suspension of the submicron particle docetaxel, pending approval.

The news release said that NanoPac for inhalation has shown tumor reduction in a preclinical lung

cancer study after pharmacokinetic studies demonstrated an unprecedented 14-day retention of

drug in lung tissue with serious abnormalities in the tissue.

The NanOlogy submicron particle technology platform is protected by an extensive intellectual

property portfolio covering production processes, uses, formulations and specifications, as

well as composition under U.S. patent 9,814,685 valid until June 2036 covering particle size, density, surface area, drug dissolution and other aspects, the company said in the news release.

- Advertisements -
- Advertisements -

Latest News

Tarrant County reports four COVID deaths on Friday

Tarrant County Public Health reported four COVID-19 deaths on Friday, Sept. 18. The deceased include a man from Hurst in his 80s,...

3 more COVID cases linked to American’s bar crawl in Bavaria

By FRANK JORDANS and DAVID RISING Associated PressBERLIN (AP) — Authorities in southern Germany have recorded three more COVID-19 infections in people...

Tarrant County reports 4 COVID deaths on Thursday

 Tarrant County Public Health reported four COVID-19 deaths on Thursday, Sept. 17. The deceased include a man from Fort Worth in his...

MedStar offers onsite flu vaccine clinics

With the presence of COVID-19, there is additional concern about this year’s flu season, the City of Fort Worth said in a...

Tarrant County reports 7 COVID deaths on Tuesday and Wednesday

Tarrant County Public Health reported four COVID-19 deaths on Wednesday and three on Tuesday.The deceased include a man from Fort Worth in...